The Cooper Companies, Inc. (COO)

Executive Summary / Key Takeaways

• Operational Turnaround Delivering Tangible Results: A completed reorganization in Q4 2025 is generating $50 million in annual pretax savings while resolved MyDay manufacturing constraints enable aggressive global rollout, creating a rare combination of margin expansion and accelerated revenue capture in the premium daily lens market.

• Market Leadership Under Competitive Siege: CooperVision's 18th consecutive year of market share gains masks growing pressure in Asia Pacific, where legacy hydrogel products are losing ground to aggressive pricing, while CooperSurgical's fertility business shows early recovery signs but remains vulnerable to regional softness and delayed capital purchases.

• Strategic Review as Potential Catalyst: A formal strategic review initiated in December 2025, amid activist pressure arguing the two businesses "make no sense under the same roof," could unlock value from a conglomerate structure that trades at a 29% discount to its 10-year average valuation multiple.

• Valuation Disconnect with Strong Cash Generation: At $70.17 per share, COO trades at 16.4x forward earnings despite generating $159 million in quarterly free cash flow and guiding to $600-625 million for FY2026, a yield-driven story that looks compelling against peers trading at 22-38x earnings.

• Critical Execution Variables: The investment thesis hinges on three factors: whether MyDay's global rollout can offset Asia Pacific weakness, if fertility markets stabilize as management expects, and how the strategic review resolves activist demands for potential separation or enhanced focus.

Setting the Scene: A Dual-Segment Medical Device Conglomerate at an Inflection Point

The Cooper Companies, founded in 1958 and headquartered in San Ramon, California, spent its first four decades as a pure-play vision care business before embarking on a transformation that defines today's investment debate. The 1990s addition of CooperSurgical began as a small diversification, but the strategic inflection came in 2017 when the company began deploying over $3 billion to build out its women's health and fertility platform, elevating former CooperSurgical head Albert White to CEO. This history explains how a contact lens specialist became a dual-segment medical device company operating in two distinct $11 billion and $2 billion global markets, each growing 4-6% annually.

CooperVision competes as the global leader by contact lens wearers and second in market share at 26%, trailing only Johnson & Johnson's (JNJ) 37% but ahead of Alcon's (ALC) 26% and Bausch + Lomb's (BLCO) 10%. The segment generates roughly two-thirds of consolidated revenue by developing premium daily silicone hydrogel lenses, specialty toric and multifocal corrections, and the only FDA-approved myopia management product for children. CooperSurgical, representing the remaining one-third, operates in fertility treatment and women's health devices, offering everything from genomic testing to contraceptive IUDs. This bifurcation creates a strategic puzzle: two medically-oriented businesses with different customer bases (optometrists vs. fertility clinics), R&D pathways, and competitive dynamics, yet sharing overhead and capital allocation decisions.

The industry structure reveals the significance of this split. Contact lenses represent a consumable, high-margin business with strong pricing power driven by material science innovation and brand loyalty among eye care professionals. The market's shift toward daily disposables favors players with manufacturing scale and premium technology, as wearers prioritize comfort and eye health over cost. Women's health devices, conversely, depend on procedure volumes, clinic capital budgets, and regulatory pathways for new devices. Fertility treatments are elective, cyclical, and sensitive to macroeconomic confidence, while contraception faces demographic headwinds and competitive pressure from pharmaceutical alternatives. These divergent characteristics suggest the whole may be worth less than the sum of its parts—a thesis activist investors have forcefully advanced.

Technology, Products, and Strategic Differentiation: The MyDay Inflection and MiSight Moat

CooperVision's competitive advantage rests on proprietary silicone hydrogel technology that delivers superior oxygen permeability and moisture retention, supporting premium pricing and customer loyalty. The MyDay premium daily silicone hydrogel portfolio represents the central growth engine, having resolved manufacturing constraints by Q3 2025 that previously limited global rollout. This resolution unlocks a multi-year revenue acceleration as the company pursues new contracts aggressively across all three regions. MyDay multifocal, Energys, and toric variants each grew over 15% in Q1 2026, with toric offering the broadest SKU range in the industry—a critical differentiator for astigmatism patients that drives practitioner preference and switching costs.

The MiSight 1 day lens stands as CooperVision's most defensible moat as the first and only FDA-approved product to slow myopia progression in children aged 8-12, with additional approvals in Japan and China. Q1 2026 sales grew 23% to $28 million, with the MyDay MiSight launch in EMEA and MiSight's February 2026 Japan launch building momentum. The significance lies in the fact that myopia management represents a blue ocean market where CooperVision faces limited direct competition, allowing pricing power that supports corporate gross margins of 68.1%. The R&D pipeline—MyDay MiSight toric, MiSight 2 for improved efficacy, and atropine combinations—extends this advantage and creates a recurring revenue stream as children require regular lens replacements throughout their developmental years.

WetLock technology in the upgraded Clarity One Day Sphere and digital boost technology in MyDay Energys demonstrate continuous innovation that justifies premium pricing. These address specific wearer pain points, such as dryness and digital eye strain, that drive conversion from older hydrogel products and competitive brands. The technology's economic impact appears in segment gross margins that exceed 65% and enable CooperVision to gain share for 18 consecutive years despite larger competitors' scale advantages.

Financial Performance & Segment Dynamics: Evidence of Operational Leverage

Q1 2026 results provide the first clean look at the reorganization benefits and manufacturing resolution. Consolidated revenue of $1.024 billion grew 6.2% reported and 2.9% organically, with CooperVision's $695 million (+7.6% reported, +3.3% organic) driving the results. The 68.1% gross margin exceeded expectations primarily due to a lighter mix of low-margin Asia Pacific revenue, revealing that geographic mix shifts can move margins by 100+ basis points, making Asia Pacific recovery both a growth and margin driver for future quarters.

Operating income surged 13.9% to $276 million, yielding a 26.9% margin that improved 180 basis points year-over-year. This expansion reflects the $50 million annual savings from Q4 2025 reorganization, which eliminated fixed costs and leveraged prior IT investments. Operating expenses as a percentage of sales declined from 43.6% to 41.2% despite heavy investment in MyDay marketing and Asia Pacific leadership upgrades, demonstrating true operational leverage.

Segment performance reveals a tale of two businesses. CooperVision's toric and multifocal lenses grew 10% reported (6% organic) while spheres grew 5% (1% organic), showing premium products driving mix improvement. Daily silicone hydrogel lenses grew 7% overall, led by double-digit MyDay growth, while legacy hydrogel products declined. This mix shift is structurally positive for margins but creates geographic disparities: Americas grew 6% organic, EMEA 4%, while Asia Pacific fell 4% due to Japan's legacy hydrogel weakness. Management's response—upgrading leadership, increasing marketing investment, and launching MyDay toric in Taiwan and MiSight in Japan—targets Q3 2026 return to growth.

CooperSurgical's $329 million revenue (+3.3% reported, +2.2% organic) showed improving fertility trends with 6% growth in that sub-segment, driven by genomics performance and consumables like ZyMot and Witness. Office and surgical grew 2% despite a 7% Paragard decline, which management anticipated following the prior year's single-hand inserter launch. Medical devices grew 6% on strong surgical OB/GYN portfolio performance, suggesting the segment can grow even with contraceptive headwinds. The 2.2% organic growth rate lags CooperVision's 3.3%, reinforcing the argument that the segments have different growth profiles that may be better valued separately.

Free cash flow of $159 million on $102 million capex demonstrates strong cash conversion, with management guiding to $600-625 million for FY2026. This represents a 4.4% free cash flow yield on the current enterprise value, supported by improving working capital and a multi-year capex cycle winding down. The balance sheet shows net debt reduced to $2.4 billion with compliance on all covenants, and a February 2026 term loan extension to 2031 for $950 million of $1.5 billion, eliminating near-term refinancing risk.

Outlook, Management Guidance, and Execution Risk

Management raised FY2026 non-GAAP EPS guidance to $4.58-4.66 while maintaining revenue guidance of $4.3-4.35 billion (4.5-5.5% organic growth), implying confidence in margin expansion despite conservative top-line assumptions. The free cash flow outlook increased to $600-625 million, with a three-year target of over $2.2 billion through 2028. This guidance embeds several critical assumptions.

First, Asia Pacific is expected to remain down in Q2 2026 before returning to growth in Q3, hinging on successful MyDay and MiSight launches and leadership changes. The 4% organic decline in Q1 was worse than expected, and management's forecast assumes they can reverse this trend despite competitive pricing pressure. If Asia Pacific continues deteriorating, it could drag overall CooperVision growth below the market rate, threatening the share gain streak and compressing margins.

Second, the fertility market recovery is projected to be gradual, potentially reaching mid-single-digit growth by year-end. Management acknowledges early signs of improvement but notes China remains weak and Middle East conflicts could impact the 2% of consolidated sales from that region. The guidance assumes no rapid rebound, which means CooperSurgical may remain a drag on consolidated growth rates, reinforcing activist arguments for separation.

Third, MiSight growth of 20-25% or higher is baked into expectations. The entry of Stellest into the U.S. market is viewed as a positive that increases overall myopia control awareness, but competitive dynamics could intensify. If MiSight fails to maintain premium pricing or share in this expanding category, it would remove a key margin driver.

Management's commentary reveals a more aggressive posture on share repurchases, with $873.9 million remaining on a $2 billion authorization. This matters because it shows capital allocation discipline—prioritizing buybacks over M&A when the stock trades at a discount—while the strategic review suggests they are open to more radical restructuring if buybacks alone don't close the valuation gap.

Risks and Asymmetries: What Could Break the Thesis

The most material near-term risk is Asia Pacific deterioration accelerating beyond Q2 2026. Management admits some competitors are taking share in Japan's older hydrogel products but insists they have not caved on price. This principled stance protects margins but could accelerate share loss if competitors sacrifice profitability for volume. The 28% decline in China's low-margin e-commerce business in Q4 2025 had minimal profit impact, but if pricing pressure spreads to premium products, it could undermine the entire Asia Pacific strategy.

CooperSurgical's fertility business faces multiple headwinds that could delay recovery. The Middle East represents 2% of consolidated sales but is a strong fertility market where conflict creates unpredictable risk. China's fertility market shows no improvement, and clinic capital purchase delays could persist if macroeconomic uncertainty continues. While genomics and consumables show strength, equipment installations remain soft, and a new competitive IUD expected in 2026 could further pressure Paragard. The segment's 8.2% operating margin in Q1 2026 (vs. CooperVision's 30.3%) demonstrates its drag on consolidated profitability.

The strategic review itself creates uncertainty. While Browning West argues the stock could more than double with a more focused strategy and Jana Partners (JANA) claims a vision business combination could yield $300-500 million in synergies, any separation would incur transition costs and potential tax consequences. The review might conclude to maintain the current structure, which could disappoint activists and pressure the stock.

Legal and regulatory risks include the HMRC payroll tax dispute , where an unfavorable appeal could cost up to $71.7 million plus interest. Broader risks include supply chain disruptions for specialized lens polymers, cybersecurity attacks, and regulatory delays for new products like MiSight 2.

Valuation Context: Historic Discount Meets Cash Generation

At $70.17 per share, Cooper Companies trades at a 12-month forward P/E of 16.4x, a steep discount to its 10-year average of 23.1x and significantly below direct peers. Alcon trades at 37.7x earnings despite 6% revenue growth and 11.7% operating margins that lag COO's 20.8%. Johnson & Johnson's Vision Care division is embedded in a conglomerate trading at 22.0x earnings, while pure-play women's health competitor Hologic (HOLX) trades at 31.4x with similar 23.0% operating margins but slower growth.

The valuation disconnect appears more pronounced on cash flow metrics. COO's price-to-free-cash-flow ratio of 27.9x and EV/EBITDA of 14.9x compare favorably to Alcon's 23.2x P/FCF and 17.6x EV/EBITDA, especially considering COO's superior operating margins and comparable growth. The company's $600-625 million free cash flow guidance for FY2026 implies a 4.4% FCF yield on enterprise value, providing substantial capital for the $2 billion share repurchase program.

Balance sheet strength supports the valuation case with net debt of $2.4 billion and debt-to-equity of 0.33x, well below Bausch + Lomb's 0.80x and Johnson & Johnson's 0.60x. The February 2026 term loan extension to 2031 eliminates refinancing risk through 2026, while the 1.34x current ratio provides adequate liquidity. The absence of a dividend focuses capital on growth and buybacks, a strategy that becomes more accretive at current valuation levels.

The activist argument for separation implicitly values CooperVision's $2.8 billion revenue run-rate and 30%+ operating margins at a premium to the current conglomerate multiple. If a standalone vision business would command Alcon's 17.6x EV/EBITDA or higher due to superior margins and share gains, the implied sum-of-parts could exceed the current $16.3 billion enterprise value even before considering CooperSurgical's $1.3 billion revenue base.

Conclusion: A Transforming Medical Device Leader at an Inflection Point

Cooper Companies sits at the intersection of operational execution and strategic optionality. The resolution of MyDay manufacturing constraints, $50 million in reorganization savings, and 18 consecutive years of market share gains demonstrate a vision business with durable competitive advantages and improving margins. Simultaneously, a formal strategic review acknowledges that the conglomerate structure may obscure value that could be realized through separation or enhanced focus.

The investment thesis balances three time horizons. Near-term, execution of MyDay's global rollout and Asia Pacific turnaround will determine whether CooperVision can sustain above-market growth. Medium-term, CooperSurgical's fertility recovery and the outcome of the strategic review will define the corporate structure and capital allocation efficiency. Long-term, proprietary technology in myopia control and premium daily lenses positions both segments to capture growing demand from demographic trends and clinical adoption.

Trading at 16.4x forward earnings while generating robust free cash flow and maintaining market leadership, COO offers an asymmetric risk/reward profile. Downside is cushioned by strong cash generation and a defensible moat in myopia control; upside could be unlocked by strategic action that closes the valuation gap with purer-play peers. The critical variables to monitor are Asia Pacific's Q3 2026 return to growth and any announcements from the strategic review.